Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | ULK1 | O75385 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378656 | 0.92 | PTK2 (0.37) | SYKSTK17ASTK17BMAPTCSNK2A1 | |
| SCHEMBL3449213 | 0.92 | SYK (0.41) | NTRK1PDGFRBKDRSYKMAPK1 | |
| SCHEMBL3448841 | 0.89 | TYRO3 (0.42) | SYKMAPTCSF1RPTK2 | |
| SCHEMBL3451173 | 0.88 | CSF1R (0.42) | SYKSTK17ASTK17BCSF1RPTK2 | |
| SCHEMBL3448739 | 0.87 | MAPT (0.36) | PDGFRBSYKMAPTCSNK2A1ULK1 | |
| SCHEMBL3448901 | 0.87 | EGFR (0.41) | NTRK1KDRSYKCSNK2A1CSF1R | |
| SCHEMBL3449613 | 0.87 | PTK2 (0.37) | SYKMAPK1STK17ASTK17BCSF1R | |
| SCHEMBL3449064 | 0.86 | CSNK2A1 (0.42) | SYKSTK17ASTK17BCSNK2A1ULK1 | |
| SCHEMBL3374098 | 0.86 | MAPT (0.40) | SYKMAPK1CSNK1A1MAPTCSNK2A1 | |
| SCHEMBL3447244 | 0.86 | PTK2 (0.42) | ULK1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | NTRK1 4774/4885PDGFRB 2785/4885KDR 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.